Forte Biosciences Australia

Forte Biosciences is a clinical-stage biopharmaceutical company focused on developing targeted therapies for autoimmune and inflammatory diseases. The company's lead program, FB-102, is a proprietary monoclonal antibody targeting CD122, the beta subunit of the IL-2 and IL-15 receptors. FB-102 is designed to modulate T-cell and NK-cell activity, with potential applications in conditions such as graft-versus-host disease, alopecia areata, and celiac disease. Forte Biosciences Australia Pty Ltd serves as the company's Australian subsidiary, facilitating clinical research and development activities within the region. The company is currently advancing FB-102 through Phase 1 clinical trials to establish safety and proof-of-mechanism.